1Little P J, Osman N, O' Brien KD. Hyperelongated bigtycan: the surreptitious initiator of atherosclerosis[J]. Curr Opin Lipidol, 2008, 19(5): 448-454.
2Nakashima Y, Wight TN, Sueishi K.. Early atheroscle- rosis in humans: role of diffuse intimal thickening and extracellular matrix proteoglycans [J]. Cardiovasc Res,2008, 79(1): 14-23.
3Noble MI, Drake-Holland A J, Vink H. Hypothesis: arterial glycocalyx dysfunction is the first step in the atherothrombotic process [J]. QJM, 2008, 101 (7): 513-518.
4Taylor KR, Gallo RL. Glycosaminoglycans and their pro- teoglycans: host-associated molecular patterns for ini- tiation and modulation of inflammation [J]. FASEB J, 2006, 20(1):9-22.
5Nakashima Y, Fujii H, Sumiyoshi S, et al. Early Hu- man Atherosclerosis: Accumulation of Lipid and Proteo- glycans in Intimal Thickenings Followed by Macrophage Infiltration[J]. Arterioscler ThrombVasc Biol, 2007, 27 (5): 303-306.
6EvankoSP, Johnson PY, Braun KR, etal. Platelet-de- rived growth factor stimulates the formation of versi- can-hyaluronan aggregates and pericellular matrix ex- panslon Biochem n arterial smooth muscle cells [J]. Arch Biophys, 2001, 394(1).. 29-38.
7Potter-Perigo S, Baker C, Tsoi C, et al. Regulation of proteoglycan synthesis by leukotriene D4 and EGF in bronchial smooth muscle cells[J]. Am J Respir Cell Mol Biol, 2004, 30(1): 101-108.
8[1]Matrisian LM. Metalloproteinases and their inhibitors in matrix remodelling. Trends Genetics, 1990, 6: 121-125
9[2]Murphy G, Stanton H, Cowell S, et al. Mechanisms for pro matrix metalloproteinase activation. APMIS, 1999, 107: 38-44
10[3]Alexander CM, Werb Z. Extracellular matrix degradation. In: Hay ED, ed. Cell biology of extracellular matrix. New York: Plenum Press, 1991, 255-302
